Home・Список акций・DexCom Inc

DexCom Inc

Закрыт

СекторЗдравоохранение

86.95 -0.29

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

85.87

Макс.

87.73

Ключевые показатели
By Trading Economics
Доход	50M 249M
Продажи	117M 1.3B
P/E Средняя по отрасли	34.51 68.51
Прибыль на акцию	0.7
Рентабельность продаж	19.039
Сотрудники	11,000
EBITDA	52M 389M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+3.68% upside

Дивиденды
By Acuity
Следующий отчет о доходах	29 окт. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	4.6B 33B
Предыдущая цена открытия	87.24
Предыдущая цена закрытия	86.95

Новостные настроения

By Acuity

21%

79%

64 / 340 Рейтинг в Healthcare

DexCom Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3 авг. 2026 г., 20:02 UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31 июл. 2026 г., 20:04 UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30 июл. 2026 г., 23:51 UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29 июл. 2026 г., 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28 июл. 2026 г., 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27 июл. 2026 г., 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24 июл. 2026 г., 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22 июл. 2026 г., 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21 июл. 2026 г., 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 июл. 2026 г., 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Сравнение c конкурентами

Изменение цены

DexCom Inc Прогноз

Целевая цена

By TipRanks

3.68% рост

Прогноз на 12 месяцев

Средняя 90.52 USD 3.68%

Максимум 112 USD

Минимум 64 USD

Основано на мнении 23 аналитиков Wall Street, спрогнозировавших целевые цены для DexCom Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

23 ratings

Покупка

Удержание

Продажа

Основано на мнении 23 аналитиков, присваивавших рейтинги акциям DexCom Inc – Данные за последние 3 месяца.

Настроения

By Acuity

64 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.